How Worrisome Is Ocugen's Latest Bad News?
Ocugen (NASDAQ: OCGN) had hoped to move forward quickly with a U.S. late-stage clinical study of its COVID-19 vaccine candidate, Covaxin. However, those plans hit a speed bump when the Food and Drug Administration (FDA) placed a clinical hold on the study. In this Motley Fool Live video recorded on Dec. 1, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how worrisome this news might be for Ocugen.
Source Fool.com
